BeiGene Ltd
688235
Company Profile
Business description
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene’s revenue.
Contact
c/o Mourant Governance Services (Cayman) Limited
94 Solaris Avenue, Camana Bay
Grand CaymanKY1-1108
CYMT: +1 345 949-4123
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
11,000
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,175.10 | 49.90 | 0.61% |
| CAC 40 | 7,461.34 | 21.02 | -0.28% |
| DAX 40 | 21,896.41 | 65.56 | -0.30% |
| Dow JONES (US) | 39,606.57 | 419.59 | 1.07% |
| FTSE 100 | 8,394.42 | 8.76 | -0.10% |
| HKSE | 21,909.76 | 162.86 | -0.74% |
| NASDAQ | 16,708.05 | 407.63 | 2.50% |
| Nikkei 225 | 35,039.15 | 170.52 | 0.49% |
| NZX 50 Index | 12,017.84 | 61.37 | 0.51% |
| S&P 500 | 5,375.86 | 88.10 | 1.67% |
| S&P/ASX 200 | 7,968.20 | 47.70 | 0.60% |
| SSE Composite Index | 3,297.29 | 0.93 | 0.03% |